Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial, demonstrating significant survival benefits for patients with advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Trial Results - The trial tested Libtayo combined with platinum-based chemotherapy against chemotherapy alone, targeting adults with advanced or metastatic NSCLC without EGFR, ALK, or ROS1 mutations [1] - Patients receiving Libtayo plus chemotherapy exhibited a 19.4% chance of survival at five years, which is more than double the 8.8% survival rate of those receiving chemotherapy alone [2] - The safety profile of Libtayo remained consistent with earlier reports, reinforcing its position as an effective first-line treatment option for advanced NSCLC [2] Group 2: Company Overview - Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases [3]